Cargando…

Comparison of Low Dose versus High Dose of Oxytocin for Initiating Uterine Contraction During Cesarean Delivery: A Randomized, Controlled, Non-Inferiority Trial

BACKGROUND: Oxytocin is used for initiating uterine contraction and preventing postpartum hemorrhage during caesarean delivery. Using a lower dosage of oxytocin may lower the risk of adverse effects while still being effective in stimulating initial uterine contraction. We aimed to compare the effec...

Descripción completa

Detalles Bibliográficos
Autores principales: Somjit, Monsicha, Surojananon, Jaruta, Kongwattanakul, Kiattisak, Kasemsiri, Cattleya, Sirisom, Monthira, Prawannoa, Khuantipa, Thepsuthammarat, Kaewjai, Komwilaisak, Ratana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7455765/
https://www.ncbi.nlm.nih.gov/pubmed/32904472
http://dx.doi.org/10.2147/IJWH.S260073
_version_ 1783575683825401856
author Somjit, Monsicha
Surojananon, Jaruta
Kongwattanakul, Kiattisak
Kasemsiri, Cattleya
Sirisom, Monthira
Prawannoa, Khuantipa
Thepsuthammarat, Kaewjai
Komwilaisak, Ratana
author_facet Somjit, Monsicha
Surojananon, Jaruta
Kongwattanakul, Kiattisak
Kasemsiri, Cattleya
Sirisom, Monthira
Prawannoa, Khuantipa
Thepsuthammarat, Kaewjai
Komwilaisak, Ratana
author_sort Somjit, Monsicha
collection PubMed
description BACKGROUND: Oxytocin is used for initiating uterine contraction and preventing postpartum hemorrhage during caesarean delivery. Using a lower dosage of oxytocin may lower the risk of adverse effects while still being effective in stimulating initial uterine contraction. We aimed to compare the effectiveness and side effects of the standard 10 IU bolus of oxytocin with those of a 5 IU bolus during caesarean delivery. PATIENTS AND METHODS: We enrolled women in a randomized, double-blind, study comparing intravenous injections of high-dose (10 IU) and low-dose (5 IU) oxytocin administered after clamping of the umbilical cord. The primary outcome was adequate uterine contraction within the first 3 mins after administration. Secondary outcomes included uterine tone, use of additional uterotonic agents, additional obstetrics procedures, and oxytocin-related adverse events. RESULTS: A total of 155 women underwent randomization, with 78 in the low-dose group and 77 in the high-dose group. The proportion of women with adequate uterine contraction during the first 3 mins was 84.6% in the low-dose group and 77.9% in the high-dose group (relative risk, 1.09; 95% CI, 0.93 to 1.26). Methylergonovine maleate was used in 14.1% of cases in the low-dose group and 36.4% in the high-dose group (relative risk, 0.40; 95% CI, 0.22 to 0.73). The necessity for additional obstetric procedures, estimated blood loss >500 mL, neonatal outcomes, and oxytocin-related adverse effects did not differ significantly between the two groups. CONCLUSION: The 5 IU bolus of oxytocin was noninferior to the standard 10 IU bolus of oxytocin for initiating adequate uterine contraction, required fewer additional uterotonic agents, and led to fewer oxytocin-related adverse events.
format Online
Article
Text
id pubmed-7455765
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-74557652020-09-04 Comparison of Low Dose versus High Dose of Oxytocin for Initiating Uterine Contraction During Cesarean Delivery: A Randomized, Controlled, Non-Inferiority Trial Somjit, Monsicha Surojananon, Jaruta Kongwattanakul, Kiattisak Kasemsiri, Cattleya Sirisom, Monthira Prawannoa, Khuantipa Thepsuthammarat, Kaewjai Komwilaisak, Ratana Int J Womens Health Original Research BACKGROUND: Oxytocin is used for initiating uterine contraction and preventing postpartum hemorrhage during caesarean delivery. Using a lower dosage of oxytocin may lower the risk of adverse effects while still being effective in stimulating initial uterine contraction. We aimed to compare the effectiveness and side effects of the standard 10 IU bolus of oxytocin with those of a 5 IU bolus during caesarean delivery. PATIENTS AND METHODS: We enrolled women in a randomized, double-blind, study comparing intravenous injections of high-dose (10 IU) and low-dose (5 IU) oxytocin administered after clamping of the umbilical cord. The primary outcome was adequate uterine contraction within the first 3 mins after administration. Secondary outcomes included uterine tone, use of additional uterotonic agents, additional obstetrics procedures, and oxytocin-related adverse events. RESULTS: A total of 155 women underwent randomization, with 78 in the low-dose group and 77 in the high-dose group. The proportion of women with adequate uterine contraction during the first 3 mins was 84.6% in the low-dose group and 77.9% in the high-dose group (relative risk, 1.09; 95% CI, 0.93 to 1.26). Methylergonovine maleate was used in 14.1% of cases in the low-dose group and 36.4% in the high-dose group (relative risk, 0.40; 95% CI, 0.22 to 0.73). The necessity for additional obstetric procedures, estimated blood loss >500 mL, neonatal outcomes, and oxytocin-related adverse effects did not differ significantly between the two groups. CONCLUSION: The 5 IU bolus of oxytocin was noninferior to the standard 10 IU bolus of oxytocin for initiating adequate uterine contraction, required fewer additional uterotonic agents, and led to fewer oxytocin-related adverse events. Dove 2020-08-24 /pmc/articles/PMC7455765/ /pubmed/32904472 http://dx.doi.org/10.2147/IJWH.S260073 Text en © 2020 Somjit et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Somjit, Monsicha
Surojananon, Jaruta
Kongwattanakul, Kiattisak
Kasemsiri, Cattleya
Sirisom, Monthira
Prawannoa, Khuantipa
Thepsuthammarat, Kaewjai
Komwilaisak, Ratana
Comparison of Low Dose versus High Dose of Oxytocin for Initiating Uterine Contraction During Cesarean Delivery: A Randomized, Controlled, Non-Inferiority Trial
title Comparison of Low Dose versus High Dose of Oxytocin for Initiating Uterine Contraction During Cesarean Delivery: A Randomized, Controlled, Non-Inferiority Trial
title_full Comparison of Low Dose versus High Dose of Oxytocin for Initiating Uterine Contraction During Cesarean Delivery: A Randomized, Controlled, Non-Inferiority Trial
title_fullStr Comparison of Low Dose versus High Dose of Oxytocin for Initiating Uterine Contraction During Cesarean Delivery: A Randomized, Controlled, Non-Inferiority Trial
title_full_unstemmed Comparison of Low Dose versus High Dose of Oxytocin for Initiating Uterine Contraction During Cesarean Delivery: A Randomized, Controlled, Non-Inferiority Trial
title_short Comparison of Low Dose versus High Dose of Oxytocin for Initiating Uterine Contraction During Cesarean Delivery: A Randomized, Controlled, Non-Inferiority Trial
title_sort comparison of low dose versus high dose of oxytocin for initiating uterine contraction during cesarean delivery: a randomized, controlled, non-inferiority trial
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7455765/
https://www.ncbi.nlm.nih.gov/pubmed/32904472
http://dx.doi.org/10.2147/IJWH.S260073
work_keys_str_mv AT somjitmonsicha comparisonoflowdoseversushighdoseofoxytocinforinitiatinguterinecontractionduringcesareandeliveryarandomizedcontrollednoninferioritytrial
AT surojananonjaruta comparisonoflowdoseversushighdoseofoxytocinforinitiatinguterinecontractionduringcesareandeliveryarandomizedcontrollednoninferioritytrial
AT kongwattanakulkiattisak comparisonoflowdoseversushighdoseofoxytocinforinitiatinguterinecontractionduringcesareandeliveryarandomizedcontrollednoninferioritytrial
AT kasemsiricattleya comparisonoflowdoseversushighdoseofoxytocinforinitiatinguterinecontractionduringcesareandeliveryarandomizedcontrollednoninferioritytrial
AT sirisommonthira comparisonoflowdoseversushighdoseofoxytocinforinitiatinguterinecontractionduringcesareandeliveryarandomizedcontrollednoninferioritytrial
AT prawannoakhuantipa comparisonoflowdoseversushighdoseofoxytocinforinitiatinguterinecontractionduringcesareandeliveryarandomizedcontrollednoninferioritytrial
AT thepsuthammaratkaewjai comparisonoflowdoseversushighdoseofoxytocinforinitiatinguterinecontractionduringcesareandeliveryarandomizedcontrollednoninferioritytrial
AT komwilaisakratana comparisonoflowdoseversushighdoseofoxytocinforinitiatinguterinecontractionduringcesareandeliveryarandomizedcontrollednoninferioritytrial